Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03207178 |
Recruitment Status : Unknown
Verified June 2017 by Shanghai Longyao Biotechnology Inc., Ltd..
Recruitment status was: Recruiting
First Posted : July 2, 2017
Last Update Posted : July 2, 2017
|
Sponsor:
Shanghai Longyao Biotechnology Inc., Ltd.
Collaborators:
Xuzhou Medical University
Shanghai Jiao Tong University School of Medicine
Information provided by (Responsible Party):
Shanghai Longyao Biotechnology Inc., Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Unknown |
---|---|
Estimated Primary Completion Date : | February 28, 2019 |
Estimated Study Completion Date : | February 28, 2020 |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):